Core Points - A class-action lawsuit has been filed by Hagens Berman against horse betting entities, alleging that they are colluding with the assistance of AI to disadvantage everyday bettors [1] Group 1 - The lawsuit claims that the use of AI by these betting entities is illegal and creates an unfair advantage [1] - The action is aimed at protecting the interests of regular bettors who may be harmed by this alleged collusion [1]

Core Viewpoint - A securities class action lawsuit has been filed against KinderCare Learning Companies, Inc. and its executives, alleging misleading statements during its October 2024 IPO, which misrepresented the company's operations and safety record [1][2]. Group 1: Lawsuit Details - The lawsuit, Gollapalli v. KinderCare Learning Companies, Inc., seeks to represent investors who purchased KLC common stock during or traceable to the IPO [1]. - The complaint claims that KinderCare's IPO documents falsely portrayed the company as providing "the highest quality care possible," while concealing a history of serious safety and care failures [2]. - The lawsuit emphasizes that over 30% of KinderCare's revenues are derived from federal subsidies, making the alleged omissions particularly significant [3]. Group 2: Stock Performance - Since the IPO, KinderCare's stock has significantly declined from an offering price of $24 per share to lows near $9 per share, attributed to the market's realization of the company's misleading statements [4]. Group 3: Investigation and Implications - Hagens Berman is investigating the claims and encourages affected investors to consider their legal options, focusing on the alleged concealment of safety and care failures that inflated the IPO price [5][6]. - The investigation aims to determine if the failure to disclose key risks constitutes a violation of U.S. securities laws [6].

SAN FRANCISCO, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Investors in MoonLake Immunotherapeutics (NASDAQ: MLTX) saw the price of their shares crater $55.75, or about 90%, after the company announced disastrous VELA-2 trial results for sonelokimab, its highly anticipated treatment for patients with skin disease (hidradenitis suppurative or “HS”). The development and severe market reaction has prompted national shareholders rights firm Hagens Berman to open an investigation into whether MoonLake may have misled inv ...

Core Points - A New York federal court has re-opened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action, allowing new investors to apply by September 24, 2025 [1][2] - The class period for the lawsuit is from March 17, 2022, to September 22, 2022, and the case has survived a motion to dismiss [3][4] - The lawsuit alleges that Spectrum misled investors about the success of its cancer treatment drug, poziotinib, leading to a share price drop of over 37% when FDA concerns were revealed [3][4] Company Background - The federal class action, Christiansen v. Spectrum Pharmaceuticals, Inc., has been ongoing since late 2022, focusing on alleged misrepresentations regarding the efficacy of poziotinib [3][4] - Assertio Holdings (ASRT) acquired Spectrum Pharmaceuticals in July 2023, allowing investors who received ASRT shares post-acquisition to potentially represent the class [5] Legal Proceedings - The proceedings were previously stayed due to allegations of misconduct by the court-appointed lead plaintiff, which resulted in his disqualification [4] - Hagens Berman is actively encouraging investors who suffered significant losses to consider becoming the new lead plaintiff, emphasizing the importance of this role in overseeing litigation [6]

Core Viewpoint - A securities class-action lawsuit has been filed against Sable Offshore Corp. for allegedly misleading investors regarding the restart of its oil production, which led to significant investor losses [1][2]. Group 1: Allegations and Legal Proceedings - The lawsuit, Johnson v. Sable Offshore Corp., involves investors who purchased shares between May 19, 2025, and June 3, 2025, including those who participated in the secondary public offering on May 21, 2025 [2]. - Sable Offshore issued a press release on May 19 claiming it had restarted oil production, which was later contradicted by California's Lieutenant Governor, stating the activities were only "well-testing procedures" [2]. - The alleged deception was revealed on May 28, 2025, when the Lieutenant Governor's letter became public, causing Sable's stock price to drop by over 15% [3]. - On June 4, 2025, a Santa Barbara County Superior Court judge issued a temporary restraining order against Sable, prohibiting oil transportation through the Las Flores Pipeline System, further impacting the stock price [3]. Group 2: Legal Representation and Investigation - Hagens Berman, a national shareholder rights firm, is investigating the claims against Sable Offshore and is seeking information from investors who suffered substantial losses [5]. - The firm is exploring whether the company's claims about oil production and subsequent judicial actions were part of a pattern of misleading behavior that caused investor losses [5]. Group 3: Company Background - Hagens Berman has a history of representing investors and has secured over $2.9 billion in cases related to corporate negligence and wrongdoing [6].

Core Viewpoint - A New York federal court has reopened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action, allowing new investors to represent the class after the previous lead plaintiff was disqualified [1][4]. Group 1: Class Action Details - Investors who purchased Spectrum (SPPI) common shares during the Class Period (Mar. 17, 2022 – Sept. 22, 2022) and those who received shares of Assertio Holdings (ASRT) due to Assertio's acquisition of Spectrum may be eligible to represent the class [2][5]. - The federal class action, Christiansen v. Spectrum Pharmaceuticals, Inc., alleges that Spectrum misled investors about the success of its cancer treatment drug, poziotinib, leading to a share price drop of over 37% when FDA concerns were revealed [3][4]. Group 2: Legal Proceedings - The case has survived a motion to dismiss, and plaintiffs had moved for class certification, but proceedings were stayed due to allegations of misconduct by the court-appointed lead plaintiff [4]. - The new deadline for applying to be the lead plaintiff is September 24, 2025 [3]. Group 3: Hagens Berman's Role - Hagens Berman is actively investigating claims related to the case and encourages investors who suffered significant losses to consider becoming the new lead plaintiff [6]. - The firm has a history of representing investors and has secured over $2.9 billion in similar cases [7].

Core Viewpoint - A class-action lawsuit has been filed against Zillow, alleging that the company illegally increases the purchase price paid by homebuyers [1] Group 1 - The lawsuit is being represented by Hagens Berman, a law firm specializing in class-action cases [1] - The allegations suggest that Zillow's practices may be detrimental to homebuyers, potentially inflating costs [1]

Group 1 - A New York federal court has re-opened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action, allowing new investors to apply by September 24, 2025 [1][2] - The class period for the lawsuit is from March 17, 2022, to September 22, 2022, and the case has survived a motion to dismiss [3][4] - The lawsuit alleges that Spectrum misled investors about the success of its cancer treatment drug, poziotinib, leading to a share price drop of over 37% when FDA concerns were revealed [3][4] Group 2 - Assertio Holdings (ASRT) acquired Spectrum Pharmaceuticals in July 2023, allowing investors who received ASRT shares after acquiring SPPI shares during the class period to potentially represent the class [5] - Hagens Berman is encouraging investors who suffered significant losses to consider becoming the new lead plaintiff, emphasizing the importance of this role in overseeing litigation [6]

Core Viewpoint - Hagens Berman has initiated an investigation into Simulations Plus, Inc. following a significant stock price drop of approximately 25% due to alarming disclosures, including a large asset impairment charge and the termination of its independent auditor, Grant Thornton [1][3]. Financial Performance - Simulations Plus reported a net loss of $67.3 million for Q3 2025, primarily driven by a $77.2 million impairment charge related to prior acquisitions, aimed at aligning asset book values with current market values [3]. Auditor Termination - The company terminated its engagement with Grant Thornton, which had been hired just two months prior, citing the auditor's inability to finalize matters related to segment reporting and internal controls in time for the quarterly report [3]. - Grant Thornton contradicted Simulations Plus's explanation in a letter to the SEC, stating that it had raised specific concerns regarding segment reporting and internal controls that were not resolved satisfactorily at the time of termination [4]. Investigation Focus - Hagens Berman's investigation is centered on whether Simulations Plus misled investors regarding the reasons for the auditor's dismissal and whether its financial statements accurately reflected asset values [5]. - The firm is examining the discrepancies between Simulations Plus's public statements and the auditor's communications to the SEC, highlighting the potential implications for investor trust [5].

Core Viewpoint - A federal securities fraud class action lawsuit has been filed against LifeMD, alleging misleading representations regarding its financial health and growth prospects, following a significant stock price decline after its earnings report in August 2025 [1][4]. Summary by Sections Lawsuit Details - The lawsuit, titled Johnston v. LifeMD, Inc., covers the period from May 7, 2025, to August 5, 2025, claiming that LifeMD made false statements, particularly during its first-quarter results announcement on May 6, 2025, when it raised its full-year revenue and adjusted EBITDA guidance [2][4]. - The complaint asserts that LifeMD's optimistic outlook regarding its competitive position in virtual obesity care and performance from its RexMD brand was misleading, as it did not disclose significant operational challenges [2][3]. Financial Performance and Stock Impact - LifeMD's second-quarter results announced on August 5, 2025, missed revenue and earnings per share estimates, leading to a reduction in its full-year guidance. The management attributed this to "temporary elevated customer acquisition costs" and issues with patient refunds [4]. - Following the earnings call, LifeMD's stock price dropped by over 44% the next day, reflecting investor reaction to the disclosed challenges [4]. Investigation and Recovery Opportunities - Hagens Berman, a national plaintiffs' rights firm, is investigating the claims against LifeMD, focusing on whether the company was aware of but failed to disclose key operational issues [6]. - The lawsuit provides an opportunity for investors who suffered significant losses during the specified period to seek recovery of damages [5].